Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591653 | 0.88 | HDAC1 (0.40) | TRPV1HDAC1HDAC8HDAC6PKM | |
| SCHEMBL4580865 | 0.77 | MAPK14 (0.42) | HDAC1HDAC8HDAC6ALDH1A1MEN1 | |
| SCHEMBL4580715 | 0.75 | PIK3CA (0.52) | POLBALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4580963 | 0.74 | CCNA2 (0.42) | HDAC1HDAC8HDAC6GSK3BSLC6A9 | |
| SCHEMBL4580829 | 0.73 | HDAC1 (0.42) | HDAC1HDAC8HDAC6MEN1PKM | |
| SCHEMBL4581847 | 0.72 | HDAC1 (0.43) | HDAC1HDAC8HDAC6ALDH1A1MEN1 | |
| SCHEMBL4582327 | 0.71 | HDAC1 (0.47) | HDAC1HDAC8HDAC6GSK3B | |
| SCHEMBL4582888 | 0.70 | HDAC1 (0.43) | HDAC1HDAC8HDAC6ALDH1A1MEN1 | |
| SCHEMBL4580805 | 0.70 | MAPK8 (0.42) | TRPV1HDAC1HDAC8HDAC6POLB | |
| SCHEMBL4580975 | 0.70 | IKBKB (0.41) | ALDH1A1MEN1KMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323464-B2 | Pyridine and pyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | GENTEX CORPORATION | 2005-04-14 | — | — | US | disclosed |
| EP-1448555-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | Celltech R & D Limited (GB) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045941-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080258-A1 | Pyridine and pyrimidine derivatives | ROR1, MAPK1, IRAK1 | TRPV1 1367/4885HDAC1 481/4885HDAC8 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.